1. Home
  2. RXST vs CAPR Comparison

RXST vs CAPR Comparison

Compare RXST & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RXST
  • CAPR
  • Stock Information
  • Founded
  • RXST 1997
  • CAPR 2005
  • Country
  • RXST United States
  • CAPR United States
  • Employees
  • RXST N/A
  • CAPR N/A
  • Industry
  • RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RXST Health Care
  • CAPR Health Care
  • Exchange
  • RXST Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • RXST 385.0M
  • CAPR 324.6M
  • IPO Year
  • RXST 2021
  • CAPR N/A
  • Fundamental
  • Price
  • RXST $8.35
  • CAPR $7.52
  • Analyst Decision
  • RXST Hold
  • CAPR Strong Buy
  • Analyst Count
  • RXST 11
  • CAPR 7
  • Target Price
  • RXST $11.80
  • CAPR $24.71
  • AVG Volume (30 Days)
  • RXST 792.1K
  • CAPR 1.4M
  • Earning Date
  • RXST 11-06-2025
  • CAPR 11-12-2025
  • Dividend Yield
  • RXST N/A
  • CAPR N/A
  • EPS Growth
  • RXST N/A
  • CAPR N/A
  • EPS
  • RXST N/A
  • CAPR N/A
  • Revenue
  • RXST $147,059,000.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • RXST N/A
  • CAPR N/A
  • Revenue Next Year
  • RXST $6.71
  • CAPR $7,894.07
  • P/E Ratio
  • RXST N/A
  • CAPR N/A
  • Revenue Growth
  • RXST 27.68
  • CAPR N/A
  • 52 Week Low
  • RXST $6.32
  • CAPR $5.68
  • 52 Week High
  • RXST $55.57
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • RXST 42.47
  • CAPR 59.84
  • Support Level
  • RXST $8.55
  • CAPR $7.11
  • Resistance Level
  • RXST $9.39
  • CAPR $8.06
  • Average True Range (ATR)
  • RXST 0.48
  • CAPR 0.52
  • MACD
  • RXST -0.10
  • CAPR 0.20
  • Stochastic Oscillator
  • RXST 1.40
  • CAPR 87.62

About RXST RxSight Inc.

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: